Sex-Specific Improvements in Myocardial Function and Angiogenesis with SGLT-2 Inhibitor Canagliflozin in a Swine Model of Metabolic Syndrome.
Publication/Presentation Date
2-22-2025
Abstract
There is a significant body of literature to suggest that coronary artery disease (CAD) is a highly sex-specific disease. The study of sex-specific therapeutics and sex-specific responses to treatment for CAD remains underreported in the literature. Sodium-glucose transporter 2 (SGLT2) inhibitors are of growing interest in the treatment of ischemic heart disease and heart failure; however, the sex-specific response to SGLT2 inhibitors is unknown. We studied an SGLT2 inhibitor, canagliflozin, in a swine model of metabolic syndrome (MS) and chronic myocardial ischemia with emphasis on the sex-specific outcomes. Yorkshire swine (
Volume
26
Issue
5
ISSN
1422-0067
Published In/Presented At
Harris, D. D., Broadwin, M., Stone, C., Sabe, S. A., Kanuparthy, M., Nho, J. W., Muir, K. C., Abid, M. R., & Sellke, F. W. (2025). Sex-Specific Improvements in Myocardial Function and Angiogenesis with SGLT-2 Inhibitor Canagliflozin in a Swine Model of Metabolic Syndrome. International journal of molecular sciences, 26(5), 1887. https://doi.org/10.3390/ijms26051887
Disciplines
Medicine and Health Sciences
PubMedID
40076513
Department(s)
Department of Surgery, Fellows and Residents, Department of Surgery Residents
Document Type
Article
